About Shionogi
About Shionogi
About
About
Company Profile
BRAND STATEMENT
Our Company
Compliance
Corporate Governance
SHIONOGI Infectious Disease Weeks
Message from Top Management
Philosophy
Business Strategy
Business Activities
Shionogi's Strength
Group Companies
History
Policies
Compliance
Compliance Promotion Structure and Initiatives
Commitment to Tax Compliance
Ensuring High Ethical Standards and Transparency in Business Activities
Corporate Governance
Basic Views and Guidelines on Corporate Governance
Corporate Governance System
Board
Shareholdings
Sustainability
Sustainability
Sustainability
Sustainability
Material Issues
Environment
Society
Governance
Address the problem of antimicrobial resistance (AMR)
Access to healthcare
Stakeholder Engagement
Sustainability disclosure and evaluation
Sustainability-related information
Environment
Policy / Approach
Environmental Topics
Initiatives for Each Theme
Information Disclosure / Data
Society
Ensuring quality and safety in products and services
Attractive workplace
Respect Human Rights
Supply Chain Management
Social contribution activities
Governance
Corporate Governance
Risk Management
Compliance
Address the problem of antimicrobial resistance (AMR)
Our promise
Background of addressing the problem of antimicrobial resistance (AMR)
Long-term commitment to improving R&D to provide novel treatments for infectious diseases
Combating challenge of AMR
AMR
Shionogi AMR Position Paper
Access to healthcare
Developing innovative therapies to address unmet needs
Promote proper use of medicines
Improving affordability for patients in need
Improving access to healthcare services in developing countries
Stakeholder Engagement
Engagement with shareholders and investors
Engagement with customers
Engagement with employees
Engagement with society
Annual Report / Integrated Report / Environment Report
Data
External evaluation
About United Nations Global Compact
Innovation
Innovation
Innovation
Innovation
R&D
Corporate Venture Capital
Pipeline
IP Strategy
Wastewater-based Epidemiology Surveillance Service
R&D
Overview of R&D
Drug discovery
Clinical Development
Digital therapy
Investigator-Initiated Research
Open Innovation
SHIONOGI Journal
News
SPmenu
SPmenu
About
Back
About
Company Profile
SHIONOGI Journal
BRAND STATEMENT
Our Company
Compliance
Corporate Governance
SHIONOGI Infectious Disease Weeks
Back
Message from Top Management
Philosophy
Business Strategy
Business Activities
Shionogi's Strength
Group Companies
History
Policies
Back
Compliance
SHIONOGI Group Compliance Policy
Compliance Promotion Structure and Initiatives
Commitment to Tax Compliance
Ensuring High Ethical Standards and Transparency in Business Activities
Back
Corporate Governance
Basic Views and Guidelines on Corporate Governance
Corporate Governance System
Board
Shareholdings
Sustainability
Back
Sustainability
Material Issues
Environment
Society
Governance
Address the problem of antimicrobial resistance (AMR)
Access to healthcare
Stakeholder Engagement
Sustainability disclosure and evaluation
Sustainability-related information
Back
Environment
Policy / Approach
Environmental Topics
Initiatives for Each Theme
Information Disclosure / Data
Back
Society
Ensuring quality and safety in products and services
Attractive workplace
Respect Human Rights
Supply Chain Management
Social contribution activities
Back
Governance
Corporate Governance
Risk Management
Compliance
Back
Address the problem of antimicrobial resistance (AMR)
Our promise
Background of addressing the problem of antimicrobial resistance (AMR)
Long-term commitment to improving R&D to provide novel treatments for infectious diseases
Combating challenge of AMR
AMR
Shionogi AMR Position Paper
Back
Access to healthcare
Developing innovative therapies to address unmet needs
Promote proper use of medicines
Improving affordability for patients in need
Improving access to healthcare services in developing countries
Back
Stakeholder Engagement
Engagement with shareholders and investors
Engagement with customers
Engagement with employees
Engagement with society
Back
Annual Report / Integrated Report / Environment Report
Data
External evaluation
Back
About United Nations Global Compact
Innovation
Back
Innovation
R&D
Corporate Venture Capital
Pipeline
IP Strategy
Wastewater-based Epidemiology Surveillance Service
Back
R&D
Overview of R&D
Drug discovery
Clinical Development
Digital therapy
Investigator-Initiated Research
Open Innovation
SHIONOGI Journal
News
Investors
Contact Us
Careers
Search
English
Worldwide
HOME
Investors
IR Library
Integrated Report / Environment Report / Response to CDP
Integrated Report / Environment Report / Response to CDP
Integrated Report
｜
Environment Report
｜
Response to CDP
Integrated Report 2025
SHIONOGI Integrated Report 2025 [PDF 11.8MB/ 99 pages]
Introduction
SHIONOGI’s Strategies and Endeavors
Research, Produce, and Promote
SHIONOGI’s Responsibilities
Data Section
Special Feature: SHIONOGI’s Strengths in Drug Discovery - Dialogue between Two Researchers
President Isao Teshirogi and Yoriko Goto Dialogue
Please also see
SHIONOGI Journal
for the researchers' dialogue.
Click here for past reports
2024
SHIONOGI Integrated Report 2024 [PDF 10.1MB/ 132 pages]
2023
SHIONOGI Integrated Report 2023 [PDF 9.2MB/124 pages]
2022
SHIONOGI Integrated Report 2022 [PDF 10.3MB/106 pages]
2021
Shionogi Integrated Report 2021 [PDF 10.1MB/ 100 pages]
Consolidated Financial Statements Year ended March 31, 2021 with Independent Auditor’s Report
2020
Shionogi Integrated Report 2020 [PDF 6.84MB/ 100 pages]
2019
Shionogi Integrated Report 2019 [PDF 9.09MB/ 114 pages]
2018
Shionogi Integrated Report 2018 [PDF 5.43MB/82P]
2017
Shionogi Integrated Report 2017 [PDF 5.75MB/ 77 pages]
2016
Shionogi Integrated Report 2016 [PDF 5.79MB /80 pages]
2015
Shionogi Annual Report 2015 [PDF 3.59MB]
2014
Shionogi Annual Report 2014 [PDF 5.33MB]
2013
Shionogi Annual Report 2013 [PDF 4.59MB]
2012
Shionogi Annual Report 2012 [PDF 6.58MB]
2011
Shionogi Annual Report 2011 [PDF 4.99MB]
2010
Shionogi Annual Report 2010 [PDF 3.40MB]
2009
Shionogi Annual Report 2009 [PDF 5.21MB]
2008
Shionogi Annual Report 2008 [PDF 3.62MB]
2007
Shionogi Annual Report 2007 [PDF 1.07MB]
2006
Shionogi Annual Report 2006 [PDF 1.07MB]
2005
Shionogi Annual Report 2005 [PDF 1.13MB]
2004
Shionogi Annual Report 2004 [PDF 0.79MB]
2003
Shionogi Annual Report 2003 [PDF 0.96MB]
Environment Report 2025
Environment Report 2025 [PDF 23.7MB]
Environmental Databook 2025 [PDF 2.7MB]
Click here for past reports
2024
Environment Report 2024 [PDF 22.7MB]
Environmental Databook 2024 [PDF 2MB]
2023
Environment Report 2023 [PDF 6.3MB]
Environmental Databook 2023 [PDF 1.9MB]
2022
Environment Report 2022 [PDF 1.6MB]
Environmental Databook 2022 [PDF 0.4MB]
2021
Environment Report 2021 [PDF 1.6MB]
Environmental Databook 2021 [PDF 0.4MB]
2020
Environment Report 2020 [PDF 3.0MB]
2019
EHS Report 2019 [PDF 6.8MB]
Response to CDP (in Japanese)
CDP Corporate Questionnaire 2025
CDP Corporate Questionnaire 2024
CDP Climate Change 2023
CDP Climate Change 2022
CDP Water Security 2023
CDP Water Security 2022
